[
  {
    "criterion": "Provides incorrect information about sotalol dose adjustment in stage 4 CKD.",
    "axis": "accuracy",
    "point": -8
  },
  {
    "criterion": "Fails to mention monitoring of electrolytes, such as potassium and magnesium, when prescribing sotalol and eplerenone.",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Suggests not monitoring ECGs for QT prolongation when prescribing sotalol.",
    "axis": "completeness",
    "point": -8
  },
  {
    "criterion": "Does not provide a clear plan for follow-up lab tests, such as renal function and electrolytes.",
    "axis": "completeness",
    "point": -5
  },
  {
    "criterion": "Provides a vague and incomplete note, lacking specific details about sotalol dosage, monitoring, and patient instructions.",
    "axis": "completeness",
    "point": -9
  },
  {
    "criterion": "Incorrectly states that sotalol dose adjustment is not necessary in stage 4 CKD.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Fails to consider the potential interaction between sotalol and eplerenone on potassium levels.",
    "axis": "accuracy",
    "point": -6
  },
  {
    "criterion": "Provides a clear and concise note with relevant details about sotalol dosage, monitoring, and patient instructions.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Responds to the user's concerns and provides additional information about sotalol dosage and monitoring.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Provides a note that is easy to read and understand, with clear headings and bullet points.",
    "axis": "communication_quality",
    "point": 7
  },
  {
    "criterion": "Fails to provide a clear plan for patient follow-up and monitoring.",
    "axis": "instruction_following",
    "point": -7
  },
  {
    "criterion": "Provides a note that is too brief and lacks relevant details about sotalol dosage and monitoring.",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Incorrectly states that sotalol is safe to use in patients with stage 4 CKD without dose adjustment.",
    "axis": "accuracy",
    "point": -9
  },
  {
    "criterion": "Fails to consider the potential impact of sotalol on QT prolongation in patients with stage 4 CKD.",
    "axis": "accuracy",
    "point": -5
  },
  {
    "criterion": "Provides a note that is difficult to read and understand, with unclear headings and confusing language.",
    "axis": "communication_quality",
    "point": -8
  }
]